

Martin Cabero-Becerra MD, PhD
4.4K posts

@Hemasurf
“#WorldCitizen | #Hematologist focused on #CLL, #Myeloma & #ArtificialIntelligence | #Surfer when the waves call & #Skater when the streets are smooth.”


















🚫💉 End of chemo in mantle is here ? ENRICH trial (Lancet 2025) 👥 397 untreated MCL (≥60 yrs) 💊 Ibrutinib + Rituximab (IR) vs 💉Immunochemotherapy (R-CHOP / R-Benda) 📊 Primary endpoint: PFS • IR > Chemo — HR 0.69 (0.52–0.90), p = 0.0034 • 🔹 vs R-CHOP HR 0.37 (0.22–0.62) • 🔹 vs R-Benda HR 0.91 (0.66–1.25) 🕰️ Median PFS 65.3 mo vs 42.4 mo ⚰️ OS: HR 0.87 (NS) 🩸 Grade ≥3 AEs ≈ 67% (balanced) ❤️ Atrial fibrillation 7% in IR arm 💡 Takeaway: Chemo-free Ibrutinib + Rituximab delivers superior PFS vs R-CHOP in older MCL — marking a new frontline option. 📖 Lewis et al. The Lancet. 2025. DOI: 🔗doi.org/10.1016/S0140-… #OncoTwitter #Lymphoma #MCL #Haematology @OncoAlert @eha_hematology @myESMO @ASCO @TheLancetOncol



